The incidence of deep fungal infections in patients with malignancies has increased dramatically over the past decades. Majority of these infections occur in patients with hematologic malignancies due to a multitude of predisposing risk factors. However over the years due to antifungal prophylactic therapies in these patients there is an increase in anti-fungal resistance in various fungi like Candida spp. and Aspergillus spp. which is a matter of concern and needs to be dealt with. The present study was undertaken to determine the prevalence of fungemia, various risk factors predisposing to it and antifungal susceptibility of fungal isolates.